Clinical Trials Logo

Filter by:
NCT ID: NCT05040776 Withdrawn - Covid19 Clinical Trials

COVID-19 ThromboprophylaXIs Study of Novel FXIa Inhibitor Frunexian (EP-7041) in ICU Patients

Start date: October 2023
Phase: Phase 2
Study type: Interventional

This is a multicenter, open-label, single cohort study of patients with confirmed COVID-19 syndrome who based on clinical judgment require care in an intensive care unit, regardless of whether or not mechanical ventilation is in use or is anticipated. Patients should be enrolled on the first day of the ICU stay; withdrawal of prior thromboprophylaxis, if any, will follow specific protocol guidance. Enrolled patients will thereafter be administered intravenous frunexian (EP-7041) until disposition from the hospital (including post-ICU non-critical care management)

NCT ID: NCT05038384 Withdrawn - Clinical trials for Malignant Solid Neoplasm

Palliative, Rehabilitation, and Integrated Medicine Handbook for Self Care at Work

Start date: December 3, 2020
Phase:
Study type: Observational

This study investigates the usefulness of the Self Care at Work Handbook in order to generate an improved version. Information from this study may help researchers identify potential factors associated with perception and usefulness of the Self Care at Work Handbook.

NCT ID: NCT05037734 Withdrawn - Osteoarthritis Clinical Trials

A Randomized Controlled Trial for Partial Knee Arthroplasty

Start date: June 2023
Phase: N/A
Study type: Interventional

This is a prospective, multi-center, two-arm, randomized, controlled post-market study to evaluate and compare the clinical accuracy of component placement in robotic-assisted UKA and that of traditional methods.

NCT ID: NCT05035368 Withdrawn - Type I Diabetes Clinical Trials

Ladarixin as Adjunctive Therapy to Improve Insulin Sensitivity and Glucometabolic Outcomes in Type 1 Diabetes

Start date: September 30, 2021
Phase: Phase 2
Study type: Interventional

Objectives Primary study objective: To determine whether orally-administered ladarixin versus placebo adjunctive therapy improves insulin sensitivity in overweight, insulin-resistant (IR) type 1 Diabetic (T1D) adult subjects. Secondary study objectives: To determine whether orally-administered ladarixin versus placebo adjunctive therapy is safe and well-tolerated in overweight, IR T1D adult subjects.

NCT ID: NCT05032482 Withdrawn - Clinical trials for Mild Alzheimer's Disease

WeArable Neuromodulation DeVice for the TrEatment of Alzheimer's Disease

WAVE-AD
Start date: December 2023
Phase: N/A
Study type: Interventional

This is a double- blind, randomized controlled trial with an open label extension designed to evaluate the safety and potential efficacy of a non-invasive brainstem neuromodulation device for treating symptoms associated with Alzheimer's disease (AD).

NCT ID: NCT05032079 Withdrawn - Clinical trials for Ductal Carcinoma in Situ

Subzero and Scorpion Trial

Start date: November 16, 2020
Phase: N/A
Study type: Interventional

This is a prospective single-institution pilot study examining the feasibility of performing ultrasound-guided cryoablation to completely ablate breast ductal carcinoma in situ (DCIS). The study is designed such that patients meeting selection criteria will undergo cryoablation followed by surgical resection. The pathology of the surgical specimen will be used to determine the rate of complete tumor ablation. Standard adjuvant therapies otherwise remained unchanged.

NCT ID: NCT05026801 Withdrawn - Clinical trials for Respiratory Tract Infection Viral

Azithromycin Plus Hydroxychloroquine for COVID-19 Infection

Start date: February 8, 2021
Phase: Phase 3
Study type: Interventional

This is a randomized, double-blinded, Phase 3, multi-center trial of the clinical and microbiologic response of patients with a respiratory tract infection (RTI) due to coronavirus treated with a combination of azithromycin and hydroxychloroquine. Approximately 200 patients with symptoms of an RTI who test positive for SARS-CoV-2 by polymerase chain reaction (PCR) will receive a combination of azithromycin 500 mg and hydroxychloroquine 600 mg or matching placebos for six consecutive days. There will be two treatment regimens into which patients are randomized so that all patients will receive some active therapy.

NCT ID: NCT05017597 Withdrawn - Neoplasms Clinical Trials

Online Cancer-Related Fatigue Management

Start date: March 1, 2023
Phase: N/A
Study type: Interventional

Many individuals who have had cancer experience functional limitations during and after their treatments. The most common side effect from cancer treatment that restricts cancer survivors' completion of daily activities is cancer-related fatigue. Here, we propose to investigate whether an interprofessional approach that targets physiologic, psychologic, and ecological factors will minimize cancer-related fatigue and enhance daily life participation for volunteer cancer survivors living in the community. The interprofessional team will include occupational therapy professor and students from Eastern Kentucky University (EKU), physical therapy and dietitian professors and their students from the University of Dayton, and instructional design instructor from EKU. The approach will include (1) individualized exercise programs-via physical therapy; (2) problem-solving strategies including modifying the environment or activity -via occupational therapy; (3) goal development via physical and occupational therapy; and (4) cancer-related fatigue education via instructional design. We hypothesize that this approach will result in participants experiencing less fatigue, increasing their mobility, improving their quality of life, and being more satisfied with how they perform daily activities.

NCT ID: NCT05016921 Withdrawn - Clinical trials for Ventricular Tachycardia

TcMS to Treat Ventricular Tachycardia

Start date: January 1, 2024
Phase: N/A
Study type: Interventional

Open label study of transcutaneous magnetic stimulation targeting the stellate ganglion in patients with ventricular tachycardia

NCT ID: NCT05016440 Withdrawn - Preeclampsia Clinical Trials

Lisinopril for Renal Protection in Postpartum Preeclamptic Women

Start date: September 2015
Phase: N/A
Study type: Interventional

There may be a role for Lisinopril in improving renal protection in post-partum women who had preeclampsia during pregnancy. The aim of this study is to determine whether routine initiation of Lisinopril after delivery, in women who had preeclampsia while they were pregnant, can control high blood pressure and improve kidney function.